Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Diseases (2)
- Medical Cell Biology (2)
- Medical Molecular Biology (2)
- Medical Pharmacology (2)
- Medical Sciences (2)
-
- Neoplasms (2)
- Amino Acids, Peptides, and Proteins (1)
- Biochemistry, Biophysics, and Structural Biology (1)
- Cancer Biology (1)
- Carbohydrates (1)
- Cardiovascular Diseases (1)
- Cell and Developmental Biology (1)
- Chemical and Pharmacologic Phenomena (1)
- Digestive System Diseases (1)
- Life Sciences (1)
- Macromolecular Substances (1)
- Medical Biochemistry (1)
- Medical Microbiology (1)
- Medical Specialties (1)
- Medicinal and Pharmaceutical Chemistry (1)
- Molecular Biology (1)
- Oncology (1)
- Other Chemicals and Drugs (1)
- Pharmaceutics and Drug Design (1)
- Pharmacy and Pharmaceutical Sciences (1)
Articles 1 - 3 of 3
Full-Text Articles in Chemicals and Drugs
Protacs – A Novel And Rapidly Developing Field Of Targeted Protein Degradation, Hannah R. Gatley
Protacs – A Novel And Rapidly Developing Field Of Targeted Protein Degradation, Hannah R. Gatley
Theses and Dissertations
There is a continued need for new technology and strategies for tackling cancer and other diseases, and within the current century a novel therapeutic strategy has emerged in the realm of targeted protein degradation called Proteolysis-Targeting Chimeras (PROTACs). This technology specifically targets and degrades disease-causing proteins via the ubiquitin-proteasome system, and has seen an explosion of research and intrigue in both academia and industry over the past two decades. The diversity of PROTAC classes based on the E3 ligase recruiting ligand and the target protein allows for a universal molecular structure that can be customized for a specific target and …
Inhibition Of Cancer Stem Cells By Glycosaminoglycan Mimetics, Connor P. O'Hara
Inhibition Of Cancer Stem Cells By Glycosaminoglycan Mimetics, Connor P. O'Hara
Theses and Dissertations
Connor O’Hara July 29, 2019
Inhibition of Cancer Stem Cells by Glycosaminoglycan Mimetics
In the United States cancer is the second leading cause of death, with colorectal cancer (CRC) being the third deadliest cancer and expected to cause over 51,000 fatalities in 2019 alone.1 The current standard of care for CRC depends largely on the staging, location, and presence of metastasis.2 As the tumor grows and invades nearby lymph tissue and blood vessels, CRC has the opportunity to invade not only nearby tissue but also metastasize into the liver and lung (most commonly).3 The 5-year survival rate …
Dual Pi3k/Mtor Inhibition With Bez235 Augments The Therapeutic Efficacy Of Doxorubicin In Cancer Without Influencing Cardiac Function, David E. Durrant
Dual Pi3k/Mtor Inhibition With Bez235 Augments The Therapeutic Efficacy Of Doxorubicin In Cancer Without Influencing Cardiac Function, David E. Durrant
Theses and Dissertations
Cancer continues to be a leading cause death in the United States despite improved treatments. Cancerous lesions form after acquiring oncogenic driver mutations or losing tumor suppressor function in normal cells. Traditional therapies have included use of genotoxic substances that take advantage of the increased growth rate and loss of tumor suppressor function to cause cell death. One such drug is the anthracycline antibiotic doxorubicin (DOX). DOX interchelates into DNA and disrupts transcriptional machinery while also poisoning topoisomerase II. This results in single and double stranded DNA breaks, which if severe enough leads to either necrotic or apoptotic cell death. …